Which empiric syndromic treatment for urethritis?

SCOPUS: ed.jinfo:eu-repo/semantics/publishe

Headaches and syphilis do not always mean neurosyphilis: a tricky case of secondary syphilis

info:eu-repo/semantics/publishe

Is Raltegravir Indicated in the Treatment of HIV Associated Refractory Immune Thrombocytopenia? A Case Report

info:eu-repo/semantics/nonPublishe

HIV and syphilis: when do we need to perform a lumbar puncture?

info:eu-repo/semantics/nonPublishe

Syphillis Oculaire. Retrospective study of syphilitix uvetitis in a cohort of patients from CHU st Pierre Brussels

info:eu-repo/semantics/nonPublishe

Infections Invasives à Haemophilus Influenzae

info:eu-repo/semantics/nonPublishe

Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: An observational, cross-sectional study

Background Mycoplasma genitalium (MG) is a cause of urethritis. While resistance to azithromycin is increasing, routine detection of MG is not performed in Belgium, where its prevalence is unknown. The aim of this study is to determine prevalence of MG in men with urethritis. Method and findings An “in-house” amplification assay detecting MG was performed on urine of men with complaints of urethritis who consulted the emergency unit or the Sexually Transmitted Infection clinic of our public hospital in Brussels. Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) were tested on the same sample. A total of 187 men were tested. Prevalence of MG was 9% (95% Confidence Interval: 5 to 13.2%). CT was detected in 20%, NG in 22% and 56% of samples were negative for these three pathogens. Neither age, ethnic origin, sexual orientation nor HIV infection were associated with MG urethritis. Conclusion M. genitalium was identified in 9% of men with complaints of urethritis indicating that amplification assay detecting MG should be implemented in routine testing for those patients.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Does Very early Initation of HAART in Patients on TB Treatment Provide Benefit in a High Income Setting?

info:eu-repo/semantics/nonPublishe

Treatment of anal dysplasia in HIV-positive men who have sex with men in a large AIDS reference centre

Objectives: Over the last few decades, incidence of anal cancer among HIV-positive men has been on the rise. In this context, programmes of screening and treatment of anal dysplasia which is a precursor of anal cancer have been developed. The aim of our study was to describe the efficiency, side effects and outcome of anal dysplasia treatment in a population of HIV-positive men who have sex with men (MSM). Methods: We performed a retrospective study of HIV-positive MSM who received treatment for anal dysplasia between May 2010 and February 2014 in the Saint-Pierre University Hospital, Brussels. The different treatments used were electrocautery (ECA), infrared coagulation (IRC), surgical treatment and imiquimod. Results: Seventy-three HIV-infected MSM were included in the study, counting 62% of HGAIN. Median age was 41 years. Eighty-one per cent were on HAART. Median CD4 cell count was 525 cell/mm³, and 65% had undetectable viral loads. A total of 139 therapeutic interventions were recorded during the study period, and two-thirds of the enrolled patients received more than one treatment. At 540 days of follow-up, the rate of treatment response was 62%. Fifty per cent of the persistent HGAIN were metachronous lesions. No severe adverse events were recorded but frequent treatment-associated discomfort was reported, such as pain, self-limited bleeding, infection and anal irritation. Conclusion: Treatment of anal dysplasia appears to be safe and to offer short-term efficiency. However, its long-term efficiency remains unknown, especially in the HIV-positive population in which spontaneous clearance is lower and rate of recurrence higher.SCOPUS: ar.jinfo:eu-repo/semantics/publishe